yopB Antibody

What is YopB and why is it important in bacterial pathogenesis?

YopB is a 401-amino-acid protein secreted by the plasmid-encoded type III secretion system (T3SS) in pathogenic Yersinia species. It functions as a critical translocator protein that participates in forming pores in the host cell membrane, enabling the injection of bacterial effector proteins that lead to cell damage and bacterial dissemination. YopB is essential for virulence in Yersinia species, including Y. pestis (plague), Y. enterocolitica, and Y. pseudotuberculosis . This protein's conservation across Yersinia species and its essential role in pathogenesis make it an important target for antibody development and vaccine research .

How do YopB antibodies influence bacterial infection outcomes?

Anti-YopB antibodies can significantly improve host survival during Yersinia infections through multiple mechanisms:

• Neutralization of YopB's immunosuppressive effects: YopB normally suppresses tumor necrosis factor-alpha (TNF-α) release by macrophages, but anti-YopB antibodies can counteract this suppression, allowing for normal TNF-α expression and enhanced bacterial clearance .

• Interference with translocon formation: Anti-YopB antibodies can prevent proper assembly of the T3SS translocon complex in host cell membranes, thereby blocking the delivery of virulence effectors .

• Enhancement of immune clearance: YopB-specific antibodies demonstrate bactericidal activity and promote opsonophagocytic killing of Yersinia by host immune cells .

In mice orally infected with Y. enterocolitica, treatment with anti-YopB antiserum on days 3 and 5 post-infection significantly decreased bacterial recovery from Peyer's patches, correlating with increased TNF-α expression .

What are the recommended methods for evaluating YopB antibody efficacy in vitro?

Several validated in vitro assays can assess the functional efficacy of YopB antibodies:

• Serum Bactericidal Activity (SBA) - The protocol includes:

  • Mixing diluted serum containing anti-YopB antibodies with Yersinia (typically 4×10⁴ CFU)

  • Incubating with baby rabbit complement for 1 hour at 30°C with shaking (225 rpm)

  • Determining viable CFU by plating on LB agar

  • Calculating SBA titer as the reciprocal of the highest serum dilution producing >50% bacterial killing

• Opsonophagocytic Killing Activity (OPKA) - This method involves:

  • Seeding 1×10⁵ J774 murine macrophage cells overnight to form monolayers

  • Mixing Yersinia with heat-inactivated serially diluted serum containing anti-YopB antibodies

  • Adding the opsonized bacteria to J774 cell monolayers

  • Incubating for 45 minutes at 37°C in 5% CO₂

  • Determining viable CFU and calculating OPKA titers

• Translocation Inhibition Assays - These assess the ability of antibodies to block Yop delivery into host cells:

  • Infecting epithelial cells (commonly HEp-2) with Yersinia in the presence of antibodies

  • Using electrophoresis and Western blotting to detect translocated YopE (as a marker for T3SS function)

  • Normalizing translocated YopE to bacterial and host cell numbers to quantify percent inhibition

How should researchers optimize immunoblotting protocols for YopB detection?

For effective YopB detection by immunoblotting:

• Sample preparation:

  • Separate Yersinia proteins on 12.5% Tris-glycine-polyacrylamide gels

  • Transfer to PVDF membranes for optimal protein binding

• Antibody optimization:

  • Primary antibody concentrations typically range from 1:1,000 to 1:10,000 depending on antibody quality

  • Monospecific anti-YopB antibodies may require pre-absorption with bacterial acetone powders to remove non-specific binding

  • For detection of YopB in complex samples (such as membrane fractions), use Clean-Blot HRP reagent instead of standard secondary antibodies to minimize background

• Controls:

  • Include YopB-deficient mutant strains (ΔyopB) as negative controls

  • For quantification, normalize YopB signal to a bacterial housekeeping protein (such as the S2 ribosomal protein)

How do structural characteristics of YopB influence antibody binding and neutralization?

YopB contains two predicted transmembrane domains that are critical for its function in pore formation. Research has shown:

• Transmembrane domains as targets: Mutations in these domains (such as proline substitutions at codons 175-176 and 239-240) can disrupt YopB function . Antibodies targeting these regions may be particularly effective at neutralizing YopB activity.

• Epitope mapping considerations: Human monoclonal antibodies against another Yersinia antigen (F1) show that binding site specificity is crucial for protection. Similarly, characterization of anti-YopB antibody epitopes is essential for understanding protection mechanisms .

• Binding affinities: Studies on comparable protective antibodies for related bacterial antigens have shown that dissociation constants (KD) in the range of picomolar to nanomolar values correlate with protection. Researchers should evaluate anti-YopB antibody affinities using techniques like biolayer interferometry or surface plasmon resonance .

What is the mechanistic relationship between YopB and LcrV in the translocon, and how does this impact antibody design?

YopB and LcrV function together in the T3SS:

• Structural complementarity: LcrV sits at the tip of the needle and connects with the target cell through the YopB/D pore complex . This spatial arrangement suggests that:

  • Antibodies targeting both components could provide synergistic protection

  • Steric hindrance may occur when antibodies bind to LcrV, potentially blocking YopB insertion

• Functional interaction: Studies show that anti-LcrV antibodies can inhibit YopB/D translocon assembly within host membranes, mimicking the phenotypes of V knockout mutants . This suggests that:

  • The LcrV-YopB interaction is a potential antibody target

  • Combination antibody approaches may be more effective than single-target strategies

• Vaccine implications: The combination of YopB and LcrV (5 μg each) as immunogens dramatically improved vaccine efficacy (70-80%) compared to either component alone (10-30%), supporting a mechanistic synergy between these proteins .

What are the critical considerations for incorporating YopB in vaccine formulations?

When developing YopB-based vaccines, researchers should consider:

• Adjuvant selection: Studies show that YopB administered with Escherichia coli double mutant heat-labile toxin (dmLT) adjuvant significantly enhances immunogenicity. The optimal adjuvant concentration was determined to be around 50 ng when paired with 50-200 ng of YopB antigen .

• Combination strategies: YopB combined with LcrV dramatically improves protection:

  • YopB or LcrV (5 μg) alone with dmLT provided only 10-30% protection against lethal Y. enterocolitica infection

  • The combination (5 μg each) increased protection to 70-80%

  • Against Y. pestis pulmonary infection, the combination provided complete protection

• Administration route impacts:

  • Intranasal administration of YopB/LcrV+dmLT induced strong systemic IgG, mucosal antibody-secreting cells, and cytokine responses

  • Intradermal administration of YopB+dmLT also showed substantial (60%) protection in infant mice

• Age-specific responses: Infant mice immunized with YopB+dmLT or LcrV+dmLT achieved 60% protection against lethal Y. enterocolitica infection, but efficacy increased to 90-100% with the combination, suggesting age-dependent response patterns .

How do YopB antibodies compare to other Yersinia antibody targets in terms of protection breadth?

Comparative analysis of YopB antibodies versus other Yersinia antibody targets reveals:

• Cross-species protection:

  • YopB/LcrV combination vaccines afforded complete protection against Y. pestis pulmonary infection and 70-80% protection against Y. enterocolitica

  • YopB's conservation across Yersinia species makes it valuable for broad-spectrum protection

• Protection against F1-negative strains:

  • F1 is a major protective antigen for Y. pestis but is not essential for virulence

  • YopB-based protection works against F1-negative Y. pestis strains, which is critical since F1-negative strains can cause disease but would evade F1-targeted vaccines

• Protection mechanisms compared to anti-LcrV:

  • Anti-LcrV antibodies can block Yop translocation independent of IL-10, similar to YopB

  • Anti-LcrV antibodies prevent early bacterial growth by blocking delivery of Yops to host cells

  • YopB antibodies likely function through similar mechanisms but target a different component of the translocation machinery

How can researchers effectively express and purify YopB for antibody production?

Due to YopB's hydrophobic nature and membrane-associated properties, special approaches are required:

• Expression systems optimized for YopB:

  • Using pGEX-2T vectors for GST-YopB fusion proteins has proven successful

  • Co-expression with its chaperone SycD significantly improves solubility and yield

• Purification approach:

  • For antibody production, YopB has been successfully purified from SDS-PAGE gels:

    • Yop proteins are secreted from Y. pseudotuberculosis in low-calcium medium

    • Proteins are resolved on SDS-8% polyacrylamide gels

    • After Coomassie brilliant blue staining, the YopB band is excised

    • This gel fragment can be used directly for immunization

• Nanolipoprotein particles (NLPs) for solubilization:

  • Recent research demonstrates that NLPs can significantly improve YopB solubility and native structure preservation

  • YopB/D translocon complexes embedded in NLPs provide superior platforms for antibody production and protein interaction studies

What are the most reliable animal models for evaluating YopB antibody efficacy in vivo?

Based on published research, several validated models exist:

• Mouse oral infection model for Y. enterocolitica:

  • Mice are orally infected with Y. enterocolitica

  • Anti-YopB treatment is administered on days 3 and 5 post-infection

  • Bacterial recovery from Peyer's patches and TNF-α expression serve as primary endpoints

  • This model demonstrates anti-YopB antibody efficacy in decreasing bacterial load

• Intravenous challenge model for Y. pestis:

  • Mice receive either active or passive immunization with YopB-containing immunogens

  • Challenge with F1⁻ or F1⁺ Y. pestis strains via intravenous route

  • Survival and bacterial burden in organs are monitored

  • This model has demonstrated protection by anti-YopB antibodies against F1⁻ Y. pestis

• Pulmonary infection model for Y. pestis:

  • After immunization with YopB/LcrV+dmLT, mice are challenged via the pulmonary route

  • This stringent model has shown complete protection with the combination vaccine

  • Particularly relevant for biodefense research against pneumonic plague

What are the technical challenges in measuring YopB translocation inhibition by antibodies?

Researchers face several technical challenges when assessing how antibodies block YopB function:

• Distinguishing between secretion and translocation inhibition:

  • YopB secretion into culture medium versus translocation into host cells must be differentiated

  • Recommended approach: Combine secretion assays (analyzing culture supernatants) with translocation assays (detecting Yops in host cell cytoplasm)

• Quantification of translocation inhibition:

  • Use reporter systems such as YopE-TEM1 beta-lactamase fusions

  • Fractionate infected host cells to separate cytoplasmic (translocated) from bacterial fractions

  • Normalize translocated protein to both bacterial numbers (using bacterial proteins like S2) and host cell numbers (using β-actin)

• Controlling for antibody effects on bacterial adhesion:

  • Antibodies might reduce bacterial attachment rather than blocking translocation

  • Include adhesion assays where bacteria-host cell interactions are quantified by ELISA using anti-Yersinia antibodies

  • This control ensures observed effects are due to translocation inhibition rather than reduced bacterial contact